KR890016026A - 살리실산 유도체 - Google Patents

살리실산 유도체 Download PDF

Info

Publication number
KR890016026A
KR890016026A KR1019890005005A KR890005005A KR890016026A KR 890016026 A KR890016026 A KR 890016026A KR 1019890005005 A KR1019890005005 A KR 1019890005005A KR 890005005 A KR890005005 A KR 890005005A KR 890016026 A KR890016026 A KR 890016026A
Authority
KR
South Korea
Prior art keywords
physiologically acceptable
general formula
formula
addition salts
acid addition
Prior art date
Application number
KR1019890005005A
Other languages
English (en)
Inventor
쿠르마이어 한스-아돌프
베버 볼프-디이트리히
라던즈 한스-에카르트
슈리프 한스-요헨
Original Assignee
나우만, 호이만
메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나우만, 호이만, 메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁 filed Critical 나우만, 호이만
Publication of KR890016026A publication Critical patent/KR890016026A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

내용 없음

Description

살리실산 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 일반식(I)의 살리실산 유도체와 이들의 생리학적으로 허용되는 산 부가염.
    여기서, R1은 H 또는 CH3, R2는 4-(4-메틸-2-티아졸일)-피페라지노, 4-(테트라히드로-2-푸로일)-피페라지조, 4-(4-메틸-2-티아졸일)-호모피페라지노, 4-벤즈아미도피페리디노, 6,7-디메톡시- 1,2,3,4-테트라히드로이소퀴놀리노, 1-이미다졸릴, 트리브로모-1-이미다졸릴, 또는 2-(3-인돌릴)-1, 1-디메틸-에틸아미노이고, R3는 탄소원자 1 내지 4를 갖는 알콕시, NH2또는 탄소원자 1 내지 4를 갖는 알킬아미노이다.
  2. 5[1-히드록시-2-(4-(4-메틸 -2-티아졸일)-피페라지노)-에틸]-살리실아미드 및 이들의 생리학적으로 허용되는 산 부가염.
  3. 제 1 항의 일반식(I)의 살리실산 유도체 및 이들의 생리학적으로 허용되는 산부가염을 제조하는데 있어서, 다음 일반식(II)의 살리실산 유도체를 다음 일반식(III)의 염기와 반응시키거나, 또는 일반식(I)에 상응하되, 하나이상의 H원자 대신에 하나 이상의 환원성 그룹 그리고/또는 C-C결합 그리고/또는 C-N결합을 함유하는 화합물을 환원시키고/시키거나, 필요에 따라, 일반식(I)의 에스테르(R3=탄소원자 1 내지 4를 갖는 알콕시기)를 일반식 R4-NH2(여기서 R4는 H 또는 탄소원자 1 내지 4를 갖는 알킬기임)의 화합물과의 반응에 의해 일반식(I)의 아미드 (R3-NH2또는 탄소원자 1 내지 4를 갖는 알킬아미노)로 전환시키고/시키거나 일반식(I)의 염기를 산으로 처리하여 이들의 생리학적으로 허용되는 산 부가염으로 전환시키는 것을 특징으로 하는 일반식(I)의 살리실산 유도체 및 이들의 생리학적으로 허용되는 산 부가염의 제조방법.
    여기서, Z는 -CHOH-CHR1또는이고, X는 C1,Br, I 또는 반응성의 작용적으로 변형된 히드 록시기이고, R1, R2및 R3는 상술한 뜻을 갖는다.
  4. 일반식(I)의 화합물, 그리고/또는 이들의 생리학적으로 허용되는 산 부가염중 하나를 적어도 하나의 고체, 액체 또는 반액체 비히클과 또느 보조제와 함께 그리고, 필요에 따라, 다른 활성 물질 하나 또는 그이상과 조합하여 적합한 약제 형태로 전환시키는 것을 특징으로 하는 약제학적 조성물의 제조방법.
  5. 적어도 하나의 일반식(I)의 화합물 그리고/또는 이들의 생리학적으로 허용되는 염중 하나를 함유하는 것을 특징으로하는 약제학적 조성물.
  6. 질병을 억제하기 위한 제 1 항에 따른 일반식(I)의 화합물.
  7. 형압강하를 위한 일반식(I)의 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890005005A 1988-04-16 1989-04-15 살리실산 유도체 KR890016026A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3812755A DE3812755A1 (de) 1988-04-16 1988-04-16 Salicylsaeurederivate
DEP3812755.5 1988-04-16

Publications (1)

Publication Number Publication Date
KR890016026A true KR890016026A (ko) 1989-11-28

Family

ID=6352163

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890005005A KR890016026A (ko) 1988-04-16 1989-04-15 살리실산 유도체

Country Status (8)

Country Link
US (1) US4987133A (ko)
EP (1) EP0338352A3 (ko)
JP (1) JPH01311064A (ko)
KR (1) KR890016026A (ko)
AU (1) AU3268889A (ko)
DE (1) DE3812755A1 (ko)
HU (1) HUT54678A (ko)
ZA (1) ZA892759B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003242245A1 (en) * 2002-06-12 2003-12-31 Sumitomo Pharmaceuticals Co., Ltd. Indole, indazole, and benzazole derivative
US7985743B1 (en) * 2005-07-22 2011-07-26 Gene A. Tabish Topical pain reliever and method of making the same
IE20070928A1 (en) * 2007-12-21 2009-09-30 Giuliani Int Ltd Multi target ligands
CN102557947B (zh) * 2010-12-17 2015-07-15 上海医药工业研究院 一种5-溴乙酰水杨酸甲酯的制备方法
CN106380409A (zh) * 2015-08-27 2017-02-08 北京嘉事联博医药科技有限公司 一种左旋沙丁胺醇及其盐的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1595923A1 (de) * 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung
DE2726513A1 (de) * 1977-06-11 1978-12-21 Sandoz Ag Neue thiazolderivate und verfahren zu deren herstellung
GR69650B (ko) * 1978-07-20 1982-07-07 Science Union & Cie
US4255575A (en) * 1979-05-04 1981-03-10 Richardson-Merrell Inc. 2-Hydroxy-5-(1-hydroxy-2-piperazinylethyl)-benzoic acid derivatives

Also Published As

Publication number Publication date
JPH01311064A (ja) 1989-12-15
DE3812755A1 (de) 1989-10-26
US4987133A (en) 1991-01-22
EP0338352A3 (de) 1990-03-14
AU3268889A (en) 1989-10-19
ZA892759B (en) 1989-12-27
EP0338352A2 (de) 1989-10-25
HUT54678A (en) 1991-03-28

Similar Documents

Publication Publication Date Title
KR880001591A (ko) 테트라하이드로 나프탈렌 및 인단유도체
KR890002060A (ko) 옥사졸리디논 화합물
KR880013888A (ko) 신규 디티오아세탈 화합물, 그의 제조방법 및 이 화합물로 되는 제약 조성물
AU6951387A (en) Sulphonylamido benzoyl- or benzyl-polymethylene-imine derivatives useful as anti-arrythmia agents
KR910011887A (ko) 신규 a-노르-스테로이드-3-카르복실산 유도체
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
KR890000470A (ko) 2,2-디메틸크로만-3-올 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물
IL99889A0 (en) Azasteroid derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
KR890006650A (ko) 테트라하이드로-푸로 및 -티에노［2,3-c］피리딘, 약제학적 제제로서의 이의 용도 및 이의 제조방법
KR840007596A (ko) 유기인 유도체의염의 제조방법
KR870010024A (ko) 티오락탐-n-아세트산 유도체, 그의 제조방법 및 용도
EP0339671A3 (en) Derivative of caffeic acid and pharmaceutical composition containing the same
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
KR890016026A (ko) 살리실산 유도체
KR890014435A (ko) 페녹시알킬카복실산 유도체 및 이의 제조방법
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR910000713A (ko) 크로만 유도체
KR890006625A (ko) 2,2-디메틸크로멘 유도체, 그의 제조방법 및 그것을 함유하는 약학 조성물
KR940003953A (ko) 1. 4-벤조디옥산 유도체
KR910002835A (ko) 인돌 유도체
KR880701233A (ko) 새로운 비페닐 유도체와 그의 제조 방법 및 용도
KR900004697A (ko) 고콜레스테롤 혈증치료용 4,5-디아릴-2- 치환된 티오이미다졸
RU98122335A (ru) Замещенные гетероциклические бензоциклоалкены и их применение в качестве субстанций с анальгезирующим действием
KR910004585A (ko) 1,5-벤조티아제핀 유도체 및 그의 제조방법
KR910021400A (ko) 옥사졸리디논

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid